GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oxford Cannabinoid Technologies Holdings PLC (FRA:0CB) » Definitions » Minority Interest
中文

Oxford Cannabinoid Technologies Holdings (FRA:0CB) Minority Interest

: €0.00 Mil (As of Oct. 2023)
View and export this data going back to 2021. Start your Free Trial

Minority interest is the carrying amount of the equity interests owned by non-controlling shareholders, partners, or other equity holders in one or more of the entities included in the reporting entity's consolidated financial statements.

Oxford Cannabinoid Technologies Holdings's minority interest for the quarter that ended in Oct. 2023 was €0.00 Mil.


Oxford Cannabinoid Technologies Holdings Minority Interest Historical Data

The historical data trend for Oxford Cannabinoid Technologies Holdings's Minority Interest can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oxford Cannabinoid Technologies Holdings Annual Data
Trend May18 May19 May20 May21 Apr23
Minority Interest
- - - - -

Oxford Cannabinoid Technologies Holdings Semi-Annual Data
May19 Nov19 May20 Nov20 May21 Nov21 Oct22 Apr23 Oct23
Minority Interest Get a 7-Day Free Trial Premium Member Only - - - - -

Oxford Cannabinoid Technologies Holdings Minority Interest Calculation

Minority interest is the carrying amount of the equity interests owned by non-controlling shareholders, partners, or other equity holders in one or more of the entities included in the reporting entity's consolidated financial statements.


Oxford Cannabinoid Technologies Holdings (FRA:0CB) Business Description

Traded in Other Exchanges
Address
267 Banbury Road, Prama House, Oxford, GBR, OX2 7HT
Oxford Cannabinoid Technologies Holdings PLC is a pharmaceutical company engaged in cannabinoid drug development. The company uses a drug development that includes proprietary cannabinoid derivatives, natural phytocannabinoids (pCBs), and in-licensed compounds. Its primary market focus is the pain market, and OCT initially aims to develop a portfolio of four drug candidates for approval as licensed pain medicines.

Oxford Cannabinoid Technologies Holdings (FRA:0CB) Headlines

No Headlines